- Home
- VMEO vs CDNA Comparison
VMEO vs CDNA Comparison
Compare VMEO & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMEO
- CDNA
- Stock Information
- Founded
- VMEO 2004
- CDNA 1998
- Country
- VMEO United States
- CDNA United States
- Employees
- VMEO N/A
- CDNA N/A
- Industry
- VMEO Computer Software: Prepackaged Software
- CDNA Medical Specialities
- Sector
- VMEO Technology
- CDNA Health Care
- Exchange
- VMEO Nasdaq
- CDNA Nasdaq
- Market Cap
- VMEO 652.9M
- CDNA 712.2M
- IPO Year
- VMEO N/A
- CDNA 2014
- Fundamental
- Price
- VMEO $7.73
- CDNA $14.18
- Analyst Decision
- VMEO Hold
- CDNA Buy
- Analyst Count
- VMEO 4
- CDNA 8
- Target Price
- VMEO $6.81
- CDNA $26.86
- AVG Volume (30 Days)
- VMEO 6.1M
- CDNA 1.5M
- Earning Date
- VMEO 11-03-2025
- CDNA 11-03-2025
- Dividend Yield
- VMEO N/A
- CDNA N/A
- EPS Growth
- VMEO N/A
- CDNA N/A
- EPS
- VMEO 0.08
- CDNA 1.00
- Revenue
- VMEO $415,404,000.00
- CDNA $340,826,000.00
- Revenue This Year
- VMEO $3.01
- CDNA $13.02
- Revenue Next Year
- VMEO $6.06
- CDNA $12.85
- P/E Ratio
- VMEO $100.69
- CDNA $14.19
- Revenue Growth
- VMEO N/A
- CDNA 14.72
- 52 Week Low
- VMEO $3.64
- CDNA $10.96
- 52 Week High
- VMEO $7.90
- CDNA $32.97
- Technical
- Relative Strength Index (RSI)
- VMEO 91.31
- CDNA 58.33
- Support Level
- VMEO $4.03
- CDNA $13.23
- Resistance Level
- VMEO $7.78
- CDNA $13.80
- Average True Range (ATR)
- VMEO 0.12
- CDNA 0.70
- MACD
- VMEO 0.39
- CDNA 0.18
- Stochastic Oscillator
- VMEO 98.67
- CDNA 92.82
About VMEO Vimeo Inc.
Vimeo Inc is the all-in-one video software solution, providing the full breadth of video tools through a software-as-a-service model. The comprehensive and cloud-based tools of the company empower its users to create, share, collaborate and communicate with video on a single, turnkey platform. The company derives its revenue from SaaS subscription fees paid by customers for subscription plans.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.